Skip to main content
Veterinary Medicines

Suvaxyn Parvo–E Amphigen

Authorised
  • Porcine parvovirus, strain S-80, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, Inactivated

Product identification

Medicine name:
Suvaxyn Parvo–E Amphigen
Suvaxyn Parvo/E-Amphigen, injekcinė emulsija kiaulėms
Active substance:
  • Porcine parvovirus, strain S-80, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, Inactivated
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Porcine parvovirus, strain S-80, Inactivated
    94.10
    haemagglutination inhibiting unit(s)
    /
    2.00
    millilitre(s)
  • Erysipelothrix rhusiopathiae, serotype 2, Inactivated
    13.50
    relative potency
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AL01
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:
  • box containing 1 vial of 50 ml (25 doses)
  • box containing 1 vial of 20 ml (10 doses)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Manufacturing & Research Spain S.L.
  • VMD
  • PEI
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/16/2378/001-002
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0266/001
Concerned member states:
  • Austria
  • Bulgaria
  • Croatia
  • Cyprus
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovenia
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

RV2378.pdf

Lithuanian (PDF)
Published on: 27/05/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."